Estrogen Receptor Alpha Degrader Compounds for Selective Proteolysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Estrogen Receptor alpha-positive cancers, such as Tamoxifen and Fulvestrant, face challenges including activation of other genes leading to increased cancer incidence and poor drug-like properties like low bioavailability, necessitating a more selective and effective method for inhibiting Estrogen Receptor alpha-driven cell proliferation.
Innovation Solution
Development of compounds that bind to Estrogen Receptor alpha and a ubiquitin ligase, using two binding motifs conjugated via a linker to facilitate selective degradation of Estrogen Receptor alpha, thereby inhibiting cell proliferation without the side effects of existing treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Tamoxifen is used to treat Estrogen Receptor alpha-positive breast cancer, then cell proliferation is inhibited, but other genes are activated leading to increased incidence of other cancers
Solution Approach 1:
The patent employs an intermediary molecule (degrader compound) that mediates between the therapeutic goal and the harmful effect. The degrader binds to both the ubiquitin ligase and Estrogen Receptor alpha, bringing them into proximity to enable selective degradation. This intermediary approach allows targeted destruction of the harmful receptor without the broad gene activation effects of Tamoxifen.
Solution Approach 2:
The invention changes the fundamental parameter of receptor interaction from competitive binding (Tamoxifen) or antagonism (Fulvestrant) to proteasomal degradation. By altering the mechanism from preventing receptor function to destroying the receptor protein itself, the patent achieves more complete and selective inhibition of Estrogen Receptor alpha-driven proliferation without Tamoxifen's harmful gene activation.
2Reliability
If Fulvestrant is used to degrade Estrogen Receptor alpha, then cell proliferation is inhibited, but drug-like properties are poor with low bioavailability requiring intramuscular administration
Solution Approach 1:
The patent changes the chemical and structural parameters of the degrader compound to achieve both selective Estrogen Receptor alpha degradation and improved drug-like properties. The compound features two binding motifs (for ubiquitin ligase and Estrogen Receptor alpha) connected by a linker, creating a molecule with optimized pharmacokinetic properties including oral bioavailability, while maintaining the ability to induce proteasomal degradation of the target receptor.
3Reliability
If general proteasome degradation is used to inhibit Estrogen Receptor alpha, then cell proliferation is inhibited, but selectivity is lost leading to deleterious effects
Solution Approach 1:
The patent uses a specific intermediary degrader compound that mediates selective proteasomal degradation. Rather than using general proteasome inhibitors that affect all substrates, the degrader acts as a targeted intermediary that recruits the proteasome specifically to Estrogen Receptor alpha through simultaneous binding to both the receptor and ubiquitin ligase, ensuring selectivity while maintaining degradation efficacy.
Solution Approach 2:
The degrader compound is segmented into two distinct binding motifs connected by a linker. One motif binds to the ubiquitin ligase while the other binds to Estrogen Receptor alpha. This segmentation allows the single molecule to simultaneously engage both targets, bringing them into close proximity to enable selective ubiquitination and degradation of only the Estrogen Receptor alpha without affecting other proteasome substrates.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit Estrogen Receptor alpha-driven cell proliferation, offering a more selective and potentially less harmful approach compared to existing treatments, with improved bioavailability and reduced risk of secondary cancer activation.
Implementation Method 1
The compounds of the present disclosure describe compounds that may be used to bind to both Estrogen Receptor alpha and a ubiquitin ligase
Implementation Method 2
Fulvestrant's mechanism of action, where the proteasome is engaged to degrade Estrogen Receptor alpha
Data Source
AI summary
The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of estrogen-related diseases and conditions.